Later on, Ma and collaborators, through a gene expression profiling study on a case series of estrogen receptor positive (ER+) BC patients treated with adjuvant tamoxifen (TAM), have identified two genes differentially over-expressed, HOXB13 in TAM recurrences and IL17BR in non-recurrences patients, suggesting the existence of a HOXB13/IL17BR ratio to predict TAM response in BC patients [69]. Here, HOXB13 is linked to breast cancer.